 |
|
An Assessment of the Independent Effects of Olanzapine and Risperidone Exposure on the Risk of Hyperlipidemia in Schizophrenic Patients
Carol E. Koro, PhD;
Donald O. Fedder, DrPH;
Gilbert J. L'Italien, PhD;
Sheila Weiss, PhD;
Laurence S. Magder, PhD;
Julie Kreyenbuhl, PhD;
Dennis Revicki, PhD;
Robert W. Buchanan, MD
Arch Gen Psychiatry. 2002;59:1021-1026.
Background The newer antipsychotic agents exhibit a superior safety profile compared with conventional antipsychotic agents in terms of extrapyramidal symptoms. Previous studies have suggested an association between olanzapine treatment and hyperlipidemia. We evaluated this association using a large health care database.
Methods The study was derived from the England and Wales–based General Practice Research Database, composed of 3.5 million subjects followed up between June 1, 1987, and September 24, 2000. A total of 18 309 individuals diagnosed as having schizophrenia were identified. A 6:1 matched nested case-control design was used. Conditional logistic regression was used to derive adjusted odds ratios (ORs), controlling for sex, age, and other medications and disease conditions influencing lipid levels. Antipsychotic drug exposure was defined as the receipt of at least 1 prescription for an antipsychotic medication within the 3 months before the date of diagnosis of hyperlipidemia.
Results There were 1268 incident cases of hyperlipidemia in the cohort, matched to 7598 control subjects. Olanzapine use was associated with nearly a 5-fold increase in the odds of developing hyperlipidemia compared with no antipsychotic exposure (OR, 4.65; 95% confidence interval [CI], 2.44-8.85) (P<.001) and more than a 3-fold increase compared with those receiving conventional agents (OR, 3.36; 95% CI, 1.77-6.39) (P<.001). Risperidone was not associated with increased odds of hyperlipidemia compared with no antipsychotic exposure (OR, 1.12; 95% CI, 0.60-2.11) (P = .72) or conventional antipsychotic exposure (OR, 0.81; 95% CI, 0.44-1.52) (P = .52).
Conclusions We observed a strong association between olanzapine exposure and hyperlipidemia in schizophrenic patients. The possible metabolic consequences of olanzapine use should be given serious consideration by treating physicians.
From the Schools of Pharmacy (Drs Koro, Fedder, L'Italien, and Weiss) and Medicine (Drs Magder, Kreyenbuhl, and Buchanan), University of Maryland, Baltimore; Bristol-Myers Squibb, Pharmaceutical Research Institute, Wallingford, Conn (Dr L'Italien); MEDTAP International, Bethesda, Md (Dr Revicki); and the Maryland Psychiatric Research Center, Catonsville (Dr Buchanan).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Mortality and tardive dyskinesia: long-term study using the US National Death Index
Dean and Thuras
Br. J. Psychiatry 2009;194:360-364.
ABSTRACT
| FULL TEXT
Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents
Haupt et al.
Am. J. Psychiatry 2009;166:345-353.
ABSTRACT
| FULL TEXT
Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Buckley et al.
Focus 2008;6:172-179.
ABSTRACT
| FULL TEXT
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett et al.
J Psychopharmacol 2007;21:357-373.
ABSTRACT
Hyperlipidemia Following Treatment With Antipsychotic Medications
Olfson et al.
Am. J. Psychiatry 2006;163:1821-1825.
ABSTRACT
| FULL TEXT
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Lambert et al.
Am J Epidemiol 2006;164:672-681.
ABSTRACT
| FULL TEXT
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Focus 2006;4:539.
FULL TEXT
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Am. J. Psychiatry 2006;163:611-622.
ABSTRACT
| FULL TEXT
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Brixner et al.
The Annals of Pharmacotherapy 2006;40:626-632.
ABSTRACT
| FULL TEXT
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Marken and Pies
The Annals of Pharmacotherapy 2006;40:276-285.
ABSTRACT
| FULL TEXT
The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?
Bushe and Paton
J Psychopharmacol 2005;19:76-83.
ABSTRACT
A Walking Program for Outpatients in Psychiatric Rehabilitation: Pilot Study
McDevitt et al.
Biol Res Nurs 2005;7:87-97.
ABSTRACT
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman et al.
NEJM 2005;353:1209-1223.
ABSTRACT
| FULL TEXT
Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes
Leslie and Rosenheck
Psychiatr. Serv. 2005;56:803-809.
ABSTRACT
| FULL TEXT
Modern antipsychotic drugs: a critical overview
Gardner et al.
CMAJ 2005;172:1703-1711.
ABSTRACT
| FULL TEXT
Academy of Psychosomatic Medicine: Proceedings From the 51st Annual Meeting: November 18-21, 2004, Marco Island, Florida
Psychosomatics 2005;46:153-186.
FULL TEXT
Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia
Nasrallah et al.
Psychiatr. Serv. 2005;56:273-282.
ABSTRACT
| FULL TEXT
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Leslie and Rosenheck
Am. J. Psychiatry 2004;161:1709-1711.
ABSTRACT
| FULL TEXT
Physical Health Monitoring of Patients With Schizophrenia
Marder et al.
Am. J. Psychiatry 2004;161:1334-1349.
ABSTRACT
| FULL TEXT
Hyperlipidemia with Olanzapine Use
Journal Watch Cardiology 2003;2003:7-7.
FULL TEXT
Hyperlipidemia with Olanzapine Use
JWatch Psychiatry 2003;2003:7-7.
FULL TEXT
Rosack
Psychiatr. News 2002;37:41-41.
FULL TEXT
|
